Hyperprotonation Cleaning, Disinfection, and Sterilization Compositions and Methods

ABSTRACT

This invention relates to compositions and methods for cleaning, disinfection, and sterilization of hard, soft, and porous surfaces, equipment, human skin, tissues, food and vegetable surfaces, and other media which are contaminated with microorganisms such as bacteria, viruses, yeast, and molds. Particularly relevant is the microbial environment whereby bacterial communities can generate three-dimensional polymicrobial Extracellular Polymeric Substances, or EPS, biofilm communities supported by an aggregation of microorganisms growing on a substrate layer, substantially degrading the antimicrobial performance of typical cleaners, disinfectants, and sterilizers. There is great need for a composition that will reliably eradicate microorganisms across a broad spectrum, particularly polymicrobial EPS communities shrouded by self-generated biofilm layer. Such a composition is disclosed herein. The invention discloses new compositions, and methods for formulation of compositions, of weak acids, surfactants, and glycol monoesters, which achieve a level of eradication such that when tested following application, no surviving microorganisms remain. All compositions and methods disclosed herein have the further benefit of their ingredients being classified by the US Food and Drug Administration (FDA) as GRAS, or Generally Regarded As Safe for use on food and food contact surfaces; and the embodiment of the claimed invention herein contains 95% USDA Certified Biobased content, and is accepted to the USDA BioPreferred® Program.

CROSS REFERENCE TO RELATED APPLICATION

This application claims the benefit of U.S. Provisional Application No. 62/198,429 filed on Jul. 29, 2015, which is incorporated herein by reference in its entirety.

FIELD OF THE INVENTION

This invention relates to compositions and methods for cleaning, disinfection, and sterilization of hard and soft surfaces, equipment, human skin, tissues, and other media which are contaminated with microorganisms such as bacteria, viruses, yeast and molds. There is great need for a composition that will reliably eradicate microorganisms across a broad spectrum. Such a composition is disclosed herein. The invention discloses new compositions, and methods for formulation of compositions, of weak acids, surfactants, and glycol monoesters, which achieve a level of eradication such that when tested following application, no surviving microorganisms remain.

BACKGROUND

It is generally understood that cleaning and disinfecting compositions for hard and soft surfaces, equipment, and human skin and tissues do not achieve complete eradication of microbe colonies. Common cleaning and disinfecting compositions based on active ingredients such as hydrogen peroxide (e.g. Lysol) and sodium hypochlorite (e.g. Clorox) are publicly marketed as “killing 99.9% of viruses and bacteria” when applied. However, those claims are based on results of laboratory planktonic testing procedures in which the composition is applied directly to microorganisms in suspension.

Extensive research has shown that the planktonic testing environment used for assessing the efficacy of common cleaners and disinfectants does not accurately represent results in the actual environments in which microorganisms thrive. In the real world, microorganisms such as Pseudomonas aeruginosa, Bacillus anthracis, Escherichia coli, Staphylococcus aureus, Proteus vulgaris, and Listeria monocytogenes typically colonize within physical matrices known as biofilms. The microbial cells in the biofilm produce a matrix outside the microorganisms known as an “extracellular polymeric substance” (EPS), more generally referred to as “biofilms.”

The presence of EPS is known to reduce the efficacy of cleaning, disinfecting and sterilizing compositions. EPS creates physical and chemical defenses that protect the microorganisms within the matrix, resulting in substantial survival rates and regrowth. When commonly used cleaning and disinfecting compositions are applied, portions of microbial colonies that are protected by the EPS then reproduce rapidly after application. Thus, it is typical with respect to a disinfectant advertised as “killing 99.9% of viruses and bacteria” (based on applications in solution using planktonic testing), that in the real world applications where EPS is prevalent, they will kill much lower percentages, and colonies will regrow rapidly. Laboratory tests have shown products claiming “99.9%” to actually kill substantially less than 30% in the presence of biofilm, refer to Corcoran, M., et al., Dec. 20, 2013.

Moreover, real world contamination often includes combinations of different types of microorganisms within biofilm-protected colonies (polymicrobial contamination). Cleaners and disinfectants currently in general use may be effective only against certain microorganisms, and not others. The commonly used tests assess effectiveness against mono-microbial test parameters, not typical polymicrobial contamination scenarios.

Thus, the commonly used claim of cleaners and disinfectants “killing 99.9%” of microorganisms is wrong and is misleading in real world conditions where EPA is prevalent. Consumers who believe they are protecting themselves and their families by applying such compositions in actuality are leaving behind substantial bacterial and virus contamination, along with corresponding health threats.

Historically, the ability to compose and apply reliably effective broad-spectrum disinfectants, antiseptics, and sterilants has not been understood to be possible. For this reason, regulatory regimes have prohibited claims that cleaners or disinfectants result in “complete eradication” or “100% kill rates.”

There is great need for a composition that would in fact achieve total eradication of microorganisms across a broad spectrum in real world EPS conditions. However, to date, there has been no disclosure of such a composition, nor any identification of the scientific principles and methods that would facilitate the formulation of such actually effective solutions.

Scientists and regulators are continuing to conduct research regarding the nature of biofilms and their physical and chemical characteristics. The object of this invention is disclosure of compositions and methods that are of greater efficacy in cleaning, disinfecting and sterilizing against microorganisms in real world environments. It is also the object of this invention to disclose methods of formulation of compositions that are uniquely targeted to breach microorganism defenses, including biofilms, EPS, and LPS, and achieve complete levels of eradication.

Cleaning and disinfecting compositions are in widespread use for purposes of removing grime, dirt and other contamination from surfaces. Contaminated surfaces include hard surfaces and soft surfaces such as those found in household environments, in industrial environments, surfaces of food products such as fruits, vegetables and meat, and the exterior and interior surfaces of the human body.

Hard surfaces include those which are frequently encountered in offices and houses, such as countertops, walls, doors, and surfaces found in lavatories, for example fixtures such as toilets, shower stalls, bathtubs, bidets, and sinks. Facilities such hospitals, medical centers, athletic facilities, gyms, restaurants, hospitality, lodging, conferences, and the like, can pose particularly difficult challenges. Interior and exterior surfaces of equipment also can be contaminated, including surfaces of equipment used in the food, scientific and medical industries, dental treatment, health care facilities and hospitals. Contamination also occurs on surfaces of devices that are implanted in the human body or used in medical procedures, such as catheters, prosthetic cardiac valves and intrauterine devices.

In addition, certain bacterial pathogens cause or contribute to human illnesses through contact with skin surfaces or mucosal tissue. Once in humans, pathogens colonize surfaces primarily as biofilms of organisms, i.e., as thin-films of organisms attached to host tissues through complex networks of polysaccharides, proteins, and nucleic acids. Such pathogens also colonize equipment through biofilm formation.

The role of biofilms is discussed in US Patent Application 2014/0275267 (Sep. 18, 2014), which notes that: “bacterial organisms which actively populate these common surfaces may form organized communities called biofilms. Bacterial cells forming these biofilm communities assume a biological phenotype that is markedly different than their corresponding planktonic (nonsurface attached, or free-swimming) bacterial analogs (citing W. G. Characklis, “Microbial Biofouling Control” in Biofilms, Characklis and Marshall, eds., Wiley & Sons, 1990, J. W. Costerton, Annual Review of Microbiology; 1995; 49:711-45). Biofilms are a special form of contamination that have been shown to require as much 1,000 times the dose of routine biocides in order to eradicate the microorganism contained within, as compared to planktonic forms.”

Cleaners and disinfectants currently on the market are significantly ineffective in the presence of biofilms. One aspect of the problem is that biofilms have a wide range of pH. As the basis of commonly used compositions, it had been viewed that pH was homogenous across microorganism environments, around pH of 5-7. Recent studies have shown that the pH range of biofilms is broader, from as low as 3 to up to 8. In addition, biofilm pH is both variable and dynamic. In reacting to contact with certain cleaning and disinfecting compositions the pH of biofilm may change. The prior art has generally considered the problem of biofilms as a steady-state issue, assuming no variation and not testing for such variation. Thus, the industry has been focused on applying compositions without addressing the true nature of the problem. This problem creates particular challenges with respect to compositions including weak acids, which ultimately rely on the process of protonation. Dynamic pH changes in biofilm can result in equilibrium in pH at the contact layer with weak acid solutions, resulting in pH below the titration point.

Another aspect of the problem is that biofilms result in physical and chemical defenses of microorganisms that must be breached in order to disrupt the living organism within. These defenses include both the outer EPS layer of the biofilm and an inner layer of lipopolysaccharides (LPS). For example, studies have been cited suggesting that the intact LPS layer of Enterobacteriaceae protected those organisms from antibacterial compositions.

Thus, microorganisms in biofilm colonies can be considered to have two distinct defense mechanisms that may be required to be overcome: (1) the mechanism whereby the pH of the biofilm results in changing the pH at the composition contact layer bringing the pH within the titration point of the active ingredient; and (2) physical protections afforded by the EPS and LPS layers.

Current cleaners and disinfectants are not generally suited for addressing a broad spectrum range of various types of microorganisms. One problem is that there is such a variation of chemical composition and physical nature of microbes, that in order to have a broad-spectrum attack it is necessary to identify and address the lowest common denominator or common defenses. Variations include physical and chemical composition of EPS/LPS, particularly in gram-negative bacteria, which can operate to make the penetration of biocides to be ineffective. A composition seeking to be effective on a broad spectrum basis must adequately address these variations.

Examples of microorganisms that are not effectively eradicated with current cleaners and disinfectants include the following:

-   -   1. Staphylococcus aureus is a gram-positive bacterium that is a         common cause of infections. The organism is ubiquitous, with         estimates of 30-40% of humans being colonized on mucosal         surfaces. Illnesses caused by the organism range from benign         infections, such as furuncles, to life-threatening illnesses         such as toxic shock syndrome (TSS).     -   2. Bacillus anthracis is a gram-positive rod that, through         production of a cell surface capsule and other molecules and         exotoxins, causes serious illnesses, including skin,         gastrointestinal, and pulmonary anthrax. This organism is         characterized as a “category A select agent” and considered a         significant threat to human health.     -   3. Methicillin-resistant Staphylococcus aureus (MRSA) is a         bacterium responsible for several difficult-to-treat infections         in humans. It is also called oxacillin-resistant Staphylococcus         aureus (ORSA). MRSA is any strain of Staphylococcus aureus that         has developed, through the process of natural selection,         resistance to beta-lactam antibiotics, which include the         penicillins (methicillin, dicloxacillin, nafcillin, oxacillin,         etc.) and the cephalosporins.

Other examples are described in the references listed below that are incorporated by reference herein.

A primary chemical interaction which can result in the breakdown of biofilms, LPS, and microorganisms, is protonation. Protonation is a fundamental chemical reaction and is a step in many stoichiometric and catalytic processes. Protonation and deprotonation occur in most acid-base reactions and are the core of most acid-base reaction theories.

For a given compound, protonation occurs at the point when the active molecule will donate the relevant proton, which is called the titration point. For example, U.S. Pat. No. 6,255,270 discloses liquid cleaning compositions comprising: an amine oxide detergent; a quaternary disinfectant (quat); an acidifying agent, an effective amount of an electrolytic disinfecting booster and an aqueous carrier, discussing the necessity of achieving the requisite composition pH and amine oxide protonation.

The failure of certain cleaners and disinfectants to break down EPS and LPS defenses and eradicate microorganisms can result from insufficient or ineffective protonation. One problem is that protonation may require maintaining a sufficient difference in pH between the composition donating the protons and that of the surfactant layer in proximity to the microorganisms. In the event the pH of the solution goes below the titration point for the active ingredient, protonation will reduce or cease and no longer be effective in breaking down EPS and LPS defenses or in disrupting the microorganisms therein.

SUMMARY OF THE INVENTION

In accordance with the purpose(s) of the invention, as embodied and broadly described herein, the invention relates to compositions for and methods of cleaning, disinfecting, and sterilizing by contact with hard, soft, and porous surfaces, human and animal skin and tissues, fabrics, carpets, equipment, devices, and other media, such composition comprising a solution or emulsion.

BRIEF DESCRIPTION OF THE FIGURES

The accompanying figures, which are incorporated in and constitute a part of this specification, illustrate several aspects and together with the description serve to explain the principles of the invention.

FIG. 1 is a graph showing the hyperprotonation—pH balance and kill zone.

FIG. 2 shows the hyperprotonation layer at the biofilm.

FIG. 3 is a table showing the antimicrobial performance of the claimed invention with respect to Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Proteus vulgaris.

FIG. 4 is a table showing the antimicrobial performance of the claimed invention with respect to Listeria monocytogenes.

DESCRIPTION

A purpose of this invention is to disclose a newly discovered understanding of the relationship of pH of the cleaning and disinfecting composition, on the one hand, and the dynamic pH of biofilms and microorganisms within biofilms. A surfactant is employed to achieve a wetting layer at the surface of the biofilm. This surface wetting creates the equivalent of a membrane, so that osmotic pressure continues the flow of aqueous solution through the wetting layer. When the raised pH surfactant layer wets the biofilm or microorganism, the result is an increase in pH such that the pH of the surfactant layer exceeds the titration point of the weak acid. By combining a weak acid with such a surfactant layer, in proper pH-titration point balance, the invention maintains continuous and enhanced protonation in the surfactant layer. This causes ongoing creation of hydronium at the surface of the EPS. It is a catalytic process. The surfactant compounds maintaining the pH levels are not consumed in the process. These processes are depicted in FIGS. 1 and 2.

This composition effectively augments or hyper-charges the ongoing impact of the protonation of the weak acid—what is defined for the first time by this application as “hyperprotonation.” In hyperprotonation, the pH in the wetting layer remains above the titration point of the acid and thus maintains ongoing production of hydronium, H₃O, in a protonation process. By combining a weak acid with such a surfactant layer, in proper pH-titration point balance, the invention maintains enhanced protonation in the surfactant layer. By providing compositions that maintain the pH at the biofilm layer above the first titration point of the weak acid within the composition, the invention enables protonation to continue to occur, such that the EPS and LPS defenses are effectively breached.

Even after EPS and LPS defenses are breached, it also is important to apply effective antimicrobial and biocidal substances to the microbes within. For example, as explained in US Patent Application No. 2013/037430: “Some bacterial pathogens initiate human illnesses from intact or damaged mucosal or skin surfaces. Many of these pathogens are acquired from other persons or animals, from endogenous sources, or from a myriad of environmental sources. Once in humans, pathogens colonize surfaces primarily as biofilms of organisms, defined as thin-films of organisms attached to host tissues, medical devices, and other bacteria through complex networks of polysaccharides, proteins, and nucleic acids. These bacteria may also exist as planktonic (broth) cultures in some host tissue environments, such as the bloodstream and mucosal secretions. Similarly, these potential pathogens may exist as either biofilms or planktonic cultures in a myriad of non-living environments.”

US Patent Application No. 2013/037430 discusses compositions of glycerol monolaurate (GML), a naturally occurring glycerol-based compound that has previously been shown to have antimicrobial, antiviral, and anti-inflammatory properties, to be applied as a topical composition in treating microbial infections and illnesses. GML is one chemical within the broader family of glycerol monoester (GME). The class of GME compositions, including GML, have been demonstrated to have potent antibacterial activity against gram-positive cocci, and Bacillus anthracis. US Patent Application No. 2013/037430 discloses that: “unlike most antibiotics which have single bacterial targets for antibacterial activities, GML appears to target many bacterial surface signal transduction systems nonspecifically through interaction with plasma membranes. GML also inhibits exotoxin production by gram-positive bacteria at GML concentrations that do not inhibit bacterial growth. These properties are shared with the antibiotic clindamycin, a protein synthesis inhibitor. GML is also virucidal for enveloped viruses, apparently through its ability to interfere with virus fusion with mammalian cells, and through GML's ability to prevent mucosal inflammation required for some viruses to penetrate mucosal surfaces. Studies demonstrate that GML is bactericidal for aerobic and anaerobic gram-positive bacteria in broth and biofilm cultures, GML exhibits greater bactericidal activity than lauric acid, and all forms of GML exhibit antibacterial activity. Additionally, GML is bactericidal for gram-negative bacteria with Lipooligosaccharidc (LOS), a low-molecular-weight form of LPS, but GML becomes bactericidal for naturally GML-resistant Enterobacteriaceae by addition of agents that disrupt the LPS layer. Gram-negative anaerobes are susceptible to GML. Pseudomonas aeruginosa appear to be the most resistant bacteria tested, but these organisms are killed by GML at pH 5.0-6.0.”

US Patent Application No. 2013/037430 described other studies demonstrating that GML and other compounds within the family of GME have potent bactericidal activity against many microorganisms causing human illnesses, including against: gram-positive bacteria, notably gram-positive cocci; anaerobes; pathogenic clostridia; Candida; Gardnerella vaginalis; Staphylococcus aureus and Streptococcus agalactiae. This includes both aerobes and anaerobes, and gram-positive, gram-negative, and non-gram-staining bacteria.

US Patent Application No. 2013/037430 concluded that: “it is thought that GML inhibits microbial infection through one or more of several mechanisms that include, but are not limited to, direct microbial toxicity; inhibiting entry of the infectious microorganism into the vertebrate cell; inhibiting growth of the microorganism; inhibiting production or activity of virulence factors such as toxins; stabilizing the vertebrate cells; or inhibiting induction of inflammatory or immunostimulatory mediators that otherwise enhance the infectious process.”

The class of GME compositions, including GML, have been demonstrated to have potent antibacterial activity, as explained in recent NIH research reports. Schlievert, P, et al. Glycerol Monolaurate Antibacterial Activity in Broth and Biofilm Cultures, Jul. 11, 2012. Importantly, GML's biocidal effect is substantially increased in low pH. However, NIH's recent research believed that “it is unlikely that GML will be used as an antibacterial agent as suspended in aqueous solutions do to its solubility limit of 100 μg/ml in aqueous solutions at 37° C.”

It is another purpose of this invention to overcome this believed limitation and to disclose compositions comprising GMEs that are effective in breaching EPS and LPS defenses and eradicating microorganisms in the real world environment. It also the purpose of this invention to disclose a newly discovered understanding of the relationship of pH and titration dynamics in cleaning, disinfecting and sterilization compositions.

The antimicrobial performance of the claimed invention with respect to Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Proteus vulgaris, whose results are contained in FIG. 3. In all cases, the study organisms resulted in zero positive cultures after 8 minutes of contact with the invention in this embodiment.

The antimicrobial performance of the claimed invention with respect to Listeria monocytogenes, whose results are contained in FIG. 4. In all cases, the study organisms resulted in zero positive cultures after 18 minutes of contact with the invention in this embodiment.

Once EPS and LPS defenses are breached, GML, and other related compounds within the category of GME, can be considered to be effective in eradicating microorganisms within biofilm colonies, while being completely safe. GME, including GML, has been determined by the US EPA to be non-toxic; 69 FR 34937. Indeed, GML occurs naturally in honey and human breast milk. All compositions and methods disclosed herein have the further benefit of being classified by the US Food and Drug Administration (FDA) as GRAS, or Generally Regarded As Safe for use on food and food contact surfaces; and the claimed invention herein contains 95% USDA Certified Biobased content and is accepted to the USDA BioPreferred® Program.

INTERPRETATION, INCORPORATION BY REFERENCE

While aspects of the present invention can be described and claimed in a particular statutory class, such as the system statutory class, this is for convenience only and one of skill in the art will understand that each aspect of the present invention can be described and claimed in any statutory class. Unless otherwise expressly stated, it is in no way intended that any method or aspect set forth herein be construed as requiring that its steps be performed in a specific order. Accordingly, where a method claim does not specifically state in the claims or descriptions that the steps are to be limited to a specific order, it is no way intended that an order be inferred, in any respect. This holds for any possible non-express basis for interpretation, including matters of logic with respect to arrangement of steps or operational flow, plain meaning derived from grammatical organization or punctuation, or the number or type of aspects described in the specification.

As used herein, “non-liquid” means granular, powder or gel formulations which can be diluted with the aqueous carrier liquid described hereinafter to produce a mildly acidic liquid hard surface cleaning composition of the present invention. As used herein, “liquid compositions” mean the mildly acidic, liquid hard surface cleaning and disinfecting compositions of the present invention, or aqueous dilutions thereof. As used herein, all parts, percentages, ppm and ratios are based on weight of the composition and assumes the materials are 100% active unless otherwise specified.

Ranges may be used herein in shorthand, to avoid having to list and describe each value within the range. Any appropriate value within the range can be selected, where appropriate, as the upper value, lower value, or the terminus of the range. As used herein, the singular form of a word includes the plural, and vice versa, unless the context clearly dictates otherwise. Thus, the references “a”, “an”, and “the” are generally inclusive of the plurals of the respective terms. For example, reference to “a method” or “a fiber” includes a plurality of such “methods”, or “fibers.” Likewise the terms “include”, “including”, and “or” should all be construed to be inclusive, unless such a construction is clearly prohibited from the context. Similarly, the term “examples,” particularly when followed by a listing of terms, is merely exemplary and illustrative and should not be deemed exclusive or comprehensive. The term “comprising” is intended to include embodiments encompassed by the terms “consisting essentially of” and “consisting of”. Similarly, the term “consisting essentially of” is intended to include embodiments encompassed by the term “consisting of.” The methods and compositions and other advances disclosed herein are not limited to particular equipment or processes described herein because such equipment or processes may vary. Further, the terminology used herein is for describing particular embodiments only and is not intended to limit the scope of that which is disclosed or claimed. Unless defined otherwise, all technical and scientific terms, terms of art, and acronyms used herein have the meanings commonly understood by one of ordinary skill in the art in the field(s) of the invention, or in the field(s) where the term is used. Although any compositions, methods, articles of manufacture, or other means or materials similar or equivalent to those described herein can be used in the practice of the present invention, the preferred compositions, methods, articles of manufacture, or other means or materials are described herein.

All patents, patent applications, publications, technical and/or scholarly articles, and other references cited or referred to herein are in their entirety incorporated herein by reference to the extent allowed by law, as if separately set forth herein. The discussion of those references is intended merely to summarize the assertions made therein. No admission is made that any such patents, patent applications, publications or references, or any portion thereof, are relevant, material, or prior art. The right to challenge the accuracy and pertinence of any assertion of such patents, patent applications, publications, and other references as relevant, material, or prior art is specifically reserved. Although the foregoing specification and examples fully disclose and enable the present invention, they are not intended to limit the scope of the invention, which is defined by the claims appended hereto. All publications, patents and patent applications are incorporated herein by reference. While in the foregoing specification this invention has been described in relation to certain embodiments thereof, and many details have been set forth for purposes of illustration, it will be apparent to those skilled in the art that the invention is susceptible to additional embodiments and that certain of the details described herein may be varied considerably without departing from the basic principles of the invention.

The Glossary herein sets forth definitions of terms that are used herein which are incorporated herein for ease of reference. However, the definitions are for convenience only and inclusion in the Glossary shall not be construed as providing definitive constructions and definitions of the terms set for thereon.

The use of the terms “a” and “an” and “the” and similar referents in the context of describing the invention are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The terms “comprising,” “having,” “including,” and “containing” are to be construed as open-ended terms (i.e., meaning “including, but not limited to”) unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein.

All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.

Embodiments of this invention are described herein, including the best modes known to the inventors for carrying out the invention. Variations of those embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein.

Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.

GLOSSARY OF DEFINITIONS

Antimicrobial.

-   -   Effective in preventing, inhibiting, or arresting the growth or         pathogenic effects of a microorganism.

Biocide.

-   -   A biocide is a chemical substance or microorganism which can         deter, render harmless, or exert a controlling effect on any         harmful organism by chemical or biological means. Biocides are         commonly used in medicine, agriculture, forestry, and industry.         Biocidal substances and products are also employed as         anti-fouling agents or disinfectants under other circumstances:         chlorine, for example, is used as a short-life biocide in         industrial water treatment but as a disinfectant in swimming         pools. Many biocides are synthetic, but a class of natural         biocides, derived from, e.g., bacteria and plants.     -   A biocide can be:     -   a. A pesticide: this includes fungicides, herbicides,         insecticides, algicides, molluscicides, miticides and         rodenticides.     -   b. An antimicrobial: this includes germicides, antibiotics,         antibacterials, antivirals, antifungals, antiprotozoals, and         antiparasites. See also spermicide.

Biofilm.

-   -   A biofilm is any group of microorganisms in which cells stick to         each other on a surface. These adherent cells are frequently         embedded within a self-produced matrix of extracellular         polymeric substance (EPS). Biofilm extracellular polymeric         substance, which is also referred to as slime (although not         everything described as slime is a biofilm), is a polymeric         conglomeration generally composed of extracellular DNA,         proteins, and polysaccharides. Biofilms may form on living or         non-living surfaces and can be prevalent in natural, industrial         and hospital settings. The microbial cells growing in a biofilm         are physiologically distinct from planktonic cells of the same         organism, which, by contrast, are single-cells that may float or         swim in a liquid medium.     -   “Biofilm EPS” refers to an aggregate of microorganisms in which         cells adhere to each other on a surface. These adherent cells         are frequently embedded within a self-produced matrix of         extracellular polymeric substance (EPS), a generally sticky         rigid structure of polysaccharides, DNA, and other organic         contaminants. A biofilm layer is anchored firmly to a surface         and provides a protective environment in which microorganisms         grow. Bacteria, viruses, yeasts, molds, and fungi contained in         the biofilms can become dormant and therefore reduce their         uptake of nutrients and/or antimicrobial agents. Biofilms have         been found to be involved in a wide variety of microbial         infections in the body, such as urinary tract infections (UTI),         catheter infections, middle-ear infections, formation of dental         plaque, gingivitis, coating contact lenses, and serious and         potentially lethal processes such as endocarditis, infections in         cystic fibrosis, and infections of permanent indwelling devices         such as joint prostheses and heart valves. Bacterial biofilms         may impair cutaneous wound healing and reduce topical         antibacterial efficiency in healing or treating infected skin         wounds. Biofilms are also present on the removed tissue of 80%         of patients undergoing surgery for chronic sinusitis. Biofilms         can also be formed on the inert surfaces of implanted devices         such as catheters, prosthetic cardiac valves and intrauterine         devices.     -   Microbes form a biofilm in response to many factors, which may         include cellular recognition of specific or non-specific         attachment sites on a surface, nutritional cues, or in some         cases, by exposure of planktonic cells to sub-inhibitory         concentrations of antibiotics. When a cell switches to the         biofilm mode of growth, it undergoes a phenotypic shift in         behavior in which large suites of genes are differentially         regulated.     -   “Biofilm” means an aggregate of microorganisms, usually         bacterial, adhered to one another and growing on a surface. The         microbial cells in the biofilm typically produce an         extracellular three-dimensional matrix growing on a substrate         layer known as an extracellular polymeric substance (EPS).         Often, this matrix and the density of the aggregate itself         significantly increase the antibiotic resistance of the bacteria         in the biofilm. Biofilms can be involved in UTIs, ear         infections, and dental diseases such as gingivitis, and can also         form on the surface of implanted devices including prostheses,         catheters, or heart valves.

Disinfectants.

-   -   Disinfectants are antimicrobial agents that are applied to         non-living objects to destroy microorganisms that are living on         the objects. Disinfection does not necessarily kill all         microorganisms, especially resistant bacterial spores; it is         less effective than sterilization, which is an extreme physical         and/or chemical process that kills all types of life.         Disinfectants are different from other antimicrobial agents such         as antibiotics, which destroy microorganisms within the body,         and antiseptics, which destroy microorganisms on living tissue.         Disinfectants are also different from biocides—the latter are         intended to destroy all forms of life, not just microorganisms.         Disinfectants work by destroying the cell wall of microbes or         interfering with the metabolism.     -   Sanitizers are substances that simultaneously clean and         disinfect. Disinfectants are frequently used in hospitals,         dental surgeries, kitchens, and bathrooms to kill infectious         organisms.

Eradication.

-   -   Eradication means the complete destruction of a microbe colony,         as demonstrated in testing of microbes in real world settings         such as biofilms, such that no further microbes are detected in         testing following a period of application of at least 18         minutes.

Extracellular Polymeric Substances (EPS).

-   -   EPS are high-molecular weight compounds secreted by         microorganisms into their environment. EPS establish the         functional and structural integrity of biofilms, and are         considered the fundamental component that determines the         physiochemical properties of a biofilm.     -   EPS are mostly composed of polysaccharides (exopolysaccharides)         and proteins, but include other macro-molecules such as DNA,         lipids, and humic substances. EPS are the construction material         of bacterial settlements and either remain attached to the         cell's outer surface, or are secreted into its growth medium.         These compounds are important in biofilm formation and cells         attachment to surfaces. EPS constitutes 50% to 90% of a         biofilm's total organic matter.

Glycerol Monoesters (GME).

Monoesters of C8, C10, and C12 straight-chain fatty acids: glycerol monocaprylate, glycerol monocaprate, and glycerol monolaurate.

Glycerol Monolaurate (GML).

-   -   Monolaurin, also known as glycerol monolaurate, glyceryl laurate         or 1-.Lauroyl-glycerol, is a monoglyceride. It is the mono-ester         formed from glycerol and lauric acid. Monolaurin is most         commonly used as a surfactant in cosmetics, such as deodorants.         As a food additive it is also used as an emulsifier.     -   Glycerol monolaurate (GML) is a fatty acid ester of glycerol,         derivative of lauric acid, with the chemical formula C₁₅H₃₀O₄.         GML is also known in the art as glyceryl laurate or monolaurin.         GML is found naturally in breast milk and some plants, and is         used as a food and cosmetic additive. GML and other glycerides         are listed in the Generally Recognized as Safe Substances         database by the US Food and Drug Administration. GML and related         compounds have been previously disclosed in U.S. patent         application Ser. No. 10/579,108 (filed Nov. 10, 2004) and Ser.         No. 11/195,239 (filed Aug. 2, 2005), the disclosures of each of         which are herein incorporated by reference for all purposes.

Hydronium.

-   -   Hydronium is the common name for the aqueous cation H₃O+, the         type of oxonium ion produced by protonation of water. It is the         positive ion present when an Arrhenius acid is dissolved in         water, as Arrhenius acid molecules in solution give to a proton         (a positive hydrogen ion, H+) to the surrounding water molecules         (H₂O). It is the presence of hydronium ion relative to hydroxide         that determines a solution's pH. The molecules in pure water         auto-dissociate into hydronium and hydroxide ions in the         following equilibrium:

2H₂O═OH−+H₃O+

-   -   In pure water, there is an equal number of hydroxide and         hydronium ions, so it has a neutral pH of 7. A pH value less         than 7 indicates an acidic solution, and a pH value more than 7         indicates a basic solution.

Hydrophilic-Lipophilic Balance (HLB).

-   -   The hydrophilic-lipophilic balance of a surfactant is a measure         of the degree to which it is hydrophilic or lipophilic,         determined by calculating values for the different regions of         the molecule.

Lipopolysaccharides or LPS.

-   -   Lipopolysaccharides (LPS), also known as lipoglycans and         endotoxin, are large molecules consisting of a lipid and a         polysaccharide composed of O-antigen, outer core and inner core         joined by a covalent bond; they are found in the outer membrane         of Gram-negative bacteria, and elicit strong immune responses in         animals. LPS is the major component of the outer membrane of         Gram-negative bacteria, contributing greatly to the structural         integrity of the bacteria, and protecting the membrane from         certain kinds of chemical attack. LPS also increases the         negative charge of the cell membrane and helps stabilize the         overall membrane structure. It is of crucial importance to         gram-negative bacteria, whose death results if it is mutated or         removed. LPS induces a strong response from normal animal immune         systems. It has also been implicated in non-pathogenic aspects         of bacterial ecology, including surface adhesion, bacteriophage         sensitivity, and interactions with predators such as amoebae.

Methicillin-Resistant Staphylococcus aureus (MRSA).

-   -   Methicillin-resistant Staphylococcus aureus (MRSA) is a         bacterium responsible for several difficult-to-treat infections         in humans. It is also called oxacillin-resistant Staphylococcus         aureus (ORSA). MRSA is any strain of Staphylococcus aureus that         has developed, through the process of natural selection,         resistance to beta-lactam antibiotics, which include the         penicillins (methicillin, dicloxacillin, nafcillin, oxacillin,         etc.) and the cephalosporins. Strains unable to resist these         antibiotics are classified as methicillin-sensitive         Staphylococcus aureus, or MSSA. The evolution of such resistance         does not cause the organism to be more intrinsically virulent         than strains of S. aureus that have no antibiotic resistance,         but resistance does make MRSA infection more difficult to treat         with standard types of antibiotics and thus more dangerous.     -   MRSA is especially troublesome in hospitals, prisons, and         nursing homes, where patients with open wounds, invasive         devices, and weakened immune systems are at greater risk of         nosocomial infection than the general public. MRSA began as a         hospital acquired infection, but has developed limited endemic         status and is now sometimes community-acquired. The terms         HA-MRSA (healthcare-associated MRSA) and CA-MRSA (community         associated MRSA) reflect this distinction.

Microbe or Microorganism.

-   -   “Microorganism” is used herein to mean any bacteria, virus, or         fungus. In one embodiment, the formulations of the invention are         used to prevent, inhibit, or arrest the growth of one or more of         the following microorganisms: Staphylococcus aureus,         Streptococcus (e.g., S. pyogenes, S. agalacticae, or S.         pneumoniae), Haemophilus influenzae, Pseudomonas aeruginosa,         Gardnerella vaginalis, Enterobacteriaceae (e.g., Escherichia         coli), Clostridium perfringens, Chlamydia trachomatis, Candida         albicans, Human Immunodeficiency Virus (HIV), or Herpes Simplex         Virus (HSV).     -   Microorganisms are the cause of many infectious diseases. The         organisms involved include pathogenic bacteria, causing diseases         such as plague, tuberculosis and anthrax; protozoa, causing         diseases such as malaria, sleeping sickness, dysentery and         toxoplasmosis; and also fungi causing diseases such as ringworm,         candidiasis or histoplasmosis. However, other diseases such as         influenza, yellow fever or AIDS are caused by pathogenic         viruses, which are not usually classified as living organisms         and are not, therefore, microorganisms by the strict definition.

Protonation.

-   -   Protonation is a fundamental chemical reaction and is a step in         many stoichiometric and catalytic processes. Some ions and         molecules can undergo more than one protonation and are labeled         polybasic, which is true of many biological macromolecules.         Protonation and deprotonation occur in most acid-base reactions;         they are the core of most acid-base reaction theories.     -   Protonations are often rapid, in part because of the high         mobility of protons in water. The rate of protonation is related         to the acidity of the protonating species, in that protonation         by weak acids is slower than protonation of the same base by         strong acids. The rates of protonation and deprotonation can be         especially slow when protonation induces significant structural         changes.     -   In chemistry, addition of a proton to an atom, molecule, or ion.         The proton is the nucleus of the hydrogen atom; the positive         hydrogen ion, H+, consists of a single proton. An example of         protonation is the formation of the ammonium group NH₄+ from         ammonia, NH₃. Protonation often occurs in the reaction of an         acid with a base to form a salt (see acids and bases; salts).         Protonation differs from hydrogenation in that during         protonation a change in charge of the protonated species occurs,         whereas the charge is unaffected during hydrogenation.

Sanitizers.

-   -   Sanitizers are substances that simultaneously clean and         disinfect.

Sterilization.

-   -   Sterilization is a term referring to any process that eliminates         (removes) or kills all forms of life, including transmissible         agents (such as fungi, bacteria, viruses, spore forms, etc.)         present in a specified region, such as a surface, a volume of         fluid, medication, or in a compound such as biological culture         media. Sterilization can be achieved with one or more of the         following: heat, chemicals, irradiation, high pressure, and         filtration. Sterilization is distinct from disinfection,         sanitization and pasteurization in that sterilization kills or         inactivates all forms of life.     -   For high-risk applications such as medical devices and         injections, a sterility assurance level of at least 10-6 is         required by the United States Food and Drug Administration         (FDA).

Surfactant.

-   -   Surfactants are compounds that lower the surface tension (or         interfacial tension) between two liquids or between a liquid and         a solid. Surfactants may act as detergents, wetting agents,         emulsifiers, foaming agents, and dispersants. Examples include:         C2-C22 fatty acid salts such as caproic, caprylic, and capric         acid salts, lauric and myristic acid salts, and naturally         occurring oils (including when saponified) such as palm oil and         coconut oil.

Titration.

-   -   The titration of a weak acid with a strong base involves the         direct transfer of protons from the weak acid to the hydroxide         ion.

Titration Curve.

-   -   A titration curve is a curve in the plane whose x-coordinate is         the volume of titrant added since the beginning of the         titration, and whose y-coordinate is the concentration of the         analyte at the corresponding stage of the titration (in an         acid-base titration, the y-coordinate is usually the pH of the         solution).     -   In an acid-base titration, the titration curve reflects the         strength of the corresponding acid and base. For a strong acid         and a strong base, the curve will be relatively smooth and very         steep near the equivalence point. Because of this, a small         change in titrant volume near the equivalence point results in a         large pH change and many indicators would be appropriate (for         instance litmus, phenolphthalein or bromothymol blue).     -   If one reagent is a weak acid or base and the other is a strong         acid or base, the titration curve is irregular and the pH shifts         less with small additions of titrant near the equivalence point.         For example, the titration curve for the titration between         oxalic acid (a weak acid) and sodium hydroxide (a strong base)         is pictured. The equivalence point occurs between pH 8-10,         indicating the solution is basic at the equivalence point and an         indicator such as phenolphthalein would be appropriate.         Titration curves corresponding to weak bases and strong acids         are similarly behaved, with the solution being acidic at the         equivalence point and indicators such as methyl orange and         bromothymol blue being most appropriate.

Weak Acid.

-   -   An acid with pH above about 2.0 and below 7.0. All pH values         herein are measured in aqueous systems at 25° C. (77° F.).         Examples include: citric acid, lactic acid, malic acid, and         tartaric acid.

CITATION LIST Patent Literature

-   Barger; Bruce, Wierenga; Thomas James. Cleaning and Disinfecting     Compositions With Electrolytic Disinfecting Booster, U.S. Pat. No.     6,255,270 (Jul. 3, 2001) -   Benson; Keith, Mulcahy; Michael George. Hyperprotonation Cleaning,     Disinfection, and Sterilization Compositions and Methods, U.S.     Provisional Application No. 62/198,429, (Jul. 29, 2015) -   Bueg-Deeb; Maria, Deeb; Thomas. Methods and Compositions for     Cleaning and Disinfecting Surfaces, US Patent Application No.     2014/0275267 (Sep. 18, 2014) -   Schlievert; Patrick. Compositions for Topical Treatment of Microbial     Infections, US Patent Application No. 2013/037430 (Oct. 24, 2013) -   Silvester; Raymaond Neville. Amine-acid Thickening Compositions,     Patent Application Publication No. EP 0253676 A2 (Jan. 20, 1988). -   Urban; Virginia Lee. Hard Surface Cleaning Compositions and Method     of Removing Stains, U.S. Pat. No. 6,936,579 (Aug. 30, 2005) -   Whiteley; Reginald Keith, Karaman; Marilyn Emily. Biofilm Remover,     U.S. Pat. No. 8,012,461 (Sep. 6, 2011)

Non-Patent Literature Reference

-   1 Characldis, W. G., Microbial Biofouling Control in Biofilms,     Characklis and Marshall, eds., Wiley & Sons, 1990, Costerton, 0.1.     W., et al, Annual Review of Microbiology; 1995; 49:711-45. -   2 Corcoran, M., et al, Commonly Used Disinfectants Fail to Eradicate     Salmonella enterica Biofilm from Food Contact Surface Materials,     Antimicrobial Resistance and Microbial Ecology Group, Discipline of     Bacteriology, National University of Ireland, Galway, Ireland, Dec.     20, 2013. -   3 Hidalgo, G., et al., Functional Tomographic Fluorescence Imaging     of pH Microenvironments in Microbial Biofilms by Use of Silica     Nanoparticle Sensors, Applied and Environmental Microbiology.     December, 2009, volume 75, no. 23: 7426-7435. -   4 McCutcheon's; Volume 1: Detergents and Emulsifiers, North American     Edition, 2014. -   5 Ruzin, A., et al., Equivalence of Lauric Acid and Glycerol     Monolaurate as Inhibitors of Signal Transmission in Staphylococcus     aureus, Journal of Bacteriology, May 2000; 182(9): 2668-2671. -   6 Schlievert, P., et al., Glycerol Monolaurate Antibacterial     Activity in Broth and Biofilm Cultures, Department of Microbiology,     University of Iowa, and Experimental and Clinical Pharmacology,     University of Minnesota, Jul. 11, 2012. 

What is claimed is:
 1. An antimicrobial composition for use in cleaning, disinfecting, or sterilizing, comprising: a. A weak acid solution with a pH below 3.00. b. A cationic surfactant with a pH that is not less than 2.00 pH greater than the first titration point of the weak acid. c. In aqueous solution, where the ratio of the volume of weak acid solution to the volume of water is not greater than 50%. d. An emulsifier comprising not less than 0.5% (one half of one percent) (w/v) and no more than 5.0% (w/v) of the total volume of the composition. e. Wherein the surfactant, when wetting a surface or other media, creates a wetting layer. f. Such wetting layer maintaining a pH at or above the first titration point of the weak acid. g. A biocide comprising less than 1% (w/v) of the solution.
 2. The composition described in claim 1, where the biocide is a chemical in the family of glycerol monoesters, in an amount not less than 500 micrograms per milliliter (0.05%) of the composition (w/v) and such composition is emulsified to achieve a stable emulsion in accordance with the hydrophilic-lipophilic balance (HLB) system.
 3. An antimicrobial composition for use in cleaning, disinfecting, or sterilizing, comprising citric acid, a chemical in the family of glycerol monoesters, an organic cationic surfactant comprising a blend of saturated and unsaturated C2-C22 fatty acid salts, and emulsifiers, meeting the following constraints: a. The first titration point (kPa) of Citric Acid is 3.13 pH. In order to assure the pH value does not exceed the first titration point of Citric Acid, the maximum allowable pH for the concentration of constituent compositions does not exceed 3.00. b. The minimum allowable GME concentration is always greater than 500 □g/ml. By design, the minimum emulsifier composition (consisting in part of GME) is no lower than 0.50% (w/v). c. In order to maintain the designed end-product safety criteria, the minimum pH value is no lower than 2.10. d. The pH values for the range of compositions of citric acid, surfactant, and emulsifiers (consisting of GML) are as set forth in Table I below: TABLE I The Design Composition Range Combined Surfactant and Emulsifier Composition (% w/v)⁽¹⁾ pH Value at pH Value at pH Value at Citric Composition of: Composition of: Composition of Acid 1.00% Potassium Cocoate 1.50% Potassium Cocoate 2.00% Potassium Cocoate (% w/v) 0.50% Emulsifiers⁽²⁾ 0.75% Emulsifiers⁽³⁾ 1.00% Emulsifiers⁽⁴⁾  1.0% 3.32 3.79 4.26  1.5% 3.03 3.48 3.78  2.0% 2.84 3.15 3.37  2.5% 2.69 2.95 3.16  3.0% 2.59 2.78 2.99  3.5% 2.51 2.72 2.89  4.0% 2.42 2.64 2.79  5.0% 2.34 2.55 2.64  6.0% 2.26 2.42 2.51  7.0% 2.19 2.32 2.39  8.0% 2.12 2.23 2.29  9.0% 2.05 2.14 2.20 10.0% 1.99 2.06 2.11 11.0% 1.94 1.99 2.03 Notes: ⁽¹⁾The 100% composition of Laurinex RTU for the range of component values is balanced by distilled water (% w/v). ⁽²⁾The composition of GML in 0.50% Emulsifiers is 750 □g/ml. ⁽³⁾The composition of GML in 0.75% Emulsifiers is 1,125 □g/ml. ⁽⁴⁾The composition of GML in 1.00% Emulsifiers is 1,500 □g/ml.


4. The method of topically administering effective amounts of a composition as disclosed in claim 1 in a non-aqueous gel or other pharmaceutically acceptable topical carrier. In certain embodiments, the antimicrobial composition comprises a glycerol monoester (GME). In certain embodiments, the GME is glycerol linked to a C6-C22 acyl group (e.g., C(=0)C5-C21 alkyl, wherein the alkyl is branched or unbranched, saturated or unsaturated). In certain embodiments, the acyl group is branched or unbranched, saturated or unsaturated. In certain embodiments, the acyl group is unbranched and saturated. In certain embodiments, the acyl group is derived from a fatty acid. In certain embodiments, the acyl group is derived from a saturated fatty acid, e.g., caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, or behenic acid. In certain embodiments, the GME is glycerol monocaprylate (C8), glycerol monocaprate (CIO), glycerol monolaurate (CI 2, or glycerol monomyristate (CI 4). In certain embodiments, the GME is present at a concentration of about 10-10,000 μg/ml, or any value there between. In certain embodiments, the GME is GML. In certain embodiments of the present invention, the carrier is one or more non-aqueous carriers or gels. In certain embodiments, the carrier is, for example, olive oil, vegetable oil, or a petroleum jelly. In certain embodiments, the antibiotic composition is applied to a solid substrate, such as a medical device or a consumer product. In certain embodiments, the active agent is dispersed in a polymer. Aqueous solutions of acids and acidic salts have long been used in compositions for cleaning. Such compositions include toilet bowl cleaners, metal cleaners and brighteners, rust stain removers, denture cleansers, metal descalers, general hard surface cleaners and disinfectants. Thickeners such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses or modified mineral materials can also be employed with liquid carriers to form spreadable pastes, gels, ointments, soaps, and the like, for application directly to the skin of the user. Examples of useful dermatological compositions which can be used to deliver the compounds of formula to the skin are known to the art; for example, see Jacquet et al. (U.S. Pat. No. 4,608,392), Geria (U.S. Pat. No. 4,992,478), Smith et al. (U.S. Pat. No. 4,559,157) and Wortzman (U.S. Pat. No. 4,820,508).
 5. The method of topically administering effective amounts of a composition as disclosed in claim 2 in a non-aqueous gel or other pharmaceutically acceptable topical carrier. In certain embodiments, the antimicrobial composition comprises a glycerol monoester (GME). In certain embodiments, the GME is glycerol linked to a C6-C22 acyl group (e.g., C(=0)C5-C21 alkyl, wherein the alkyl is branched or unbranched, saturated or unsaturated). In certain embodiments, the acyl group is branched or unbranched, saturated or unsaturated. In certain embodiments, the acyl group is unbranched and saturated. In certain embodiments, the acyl group is derived from a fatty acid. In certain embodiments, the acyl group is derived from a saturated fatty acid, e.g., caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, or behenic acid. In certain embodiments, the GME is glycerol monocaprylate (C8), glycerol monocaprate (CIO), glycerol monolaurate (CI 2, “GML”), or glycerol monomyristate (CI 4). In certain embodiments, the GME is present at a concentration of about 10-10,000 μg/ml, or any value there between. In certain embodiments, the GME is GML. In certain embodiments of the present invention, the carrier is one or more non-aqueous carriers or gels. In certain embodiments, the carrier is, for example, olive oil, vegetable oil, or a petroleum jelly. In certain embodiments, the antibiotic composition is applied to a solid substrate, such as a medical device or a consumer product. In certain embodiments, the active agent is dispersed in a polymer. Aqueous solutions of acids and acidic salts have long been used in compositions for cleaning. Such compositions include toilet bowl cleaners, metal cleaners and brighteners, rust stain removers, denture cleansers, metal descalers, general hard surface cleaners and disinfectants. Thickeners such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses or modified mineral materials can also be employed with liquid carriers to form spreadable pastes, gels, ointments, soaps, and the like, for application directly to the skin of the user. Examples of useful dermatological compositions' which can be used to deliver the compounds of formula to the skin are known to the art; for example, see Jacquet et al. (U.S. Pat. No. 4,608,392), Geria (U.S. Pat. No. 4,992,478), Smith et al. (U.S. Pat. No. 4,559,157) and Wortzman (U.S. Pat. No. 4,820,508).
 6. The method of topically administering effective amounts of a composition as disclosed in claim 3, in a non-aqueous gel or other pharmaceutically acceptable topical carrier. In certain embodiments, the antimicrobial composition comprises a glycerol monoester (GME). In certain embodiments, the GME is glycerol linked to a C6-C22 acyl group (e.g., C(=0)C5-C21 alkyl, wherein the alkyl is branched or unbranched, saturated or unsaturated). In certain embodiments, the acyl group is branched or unbranched, saturated or unsaturated. In certain embodiments, the acyl group is unbranched and saturated. In certain embodiments, the acyl group is derived from a fatty acid. In certain embodiments, the acyl group is derived from a saturated fatty acid, e.g., caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, or behenic acid. In certain embodiments, the GME is glycerol monocaprylate (C8), glycerol monocaprate (CIO), glycerol monolaurate (CI 2, “GML”), or glycerol monomyristate (CI 4). In certain embodiments, the GME is present at a concentration of about 10-10,000 μg/ml, or any value there between. In certain embodiments, the GME is GML. In certain embodiments of the present invention, the carrier is one or more non-aqueous carriers or gels. In certain embodiments, the carrier is, for example, olive oil, vegetable oil, or a petroleum jelly. In certain embodiments, the antibiotic composition is applied to a solid substrate, such as a medical device or a consumer product. In certain embodiments, the active agent is dispersed in a polymer. Aqueous solutions of acids and acidic salts have long been used in compositions for cleaning. Such compositions include toilet bowl cleaners, metal cleaners and brighteners, rust stain removers, denture cleansers, metal descalers, general hard surface cleaners and disinfectants. Thickeners such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses or modified mineral materials can also be employed with liquid carriers to form spreadable pastes, gels, ointments, soaps, and the like, for application directly to the skin of the user. Examples of useful dermatological compositions which can be used to deliver the compounds of formula to the skin are known to the art; for example, see Jacquet et al. (U.S. Pat. No. 4,608,392), Geria (U.S. Pat. No. 4,992,478), Smith et al. (U.S. Pat. No. 4,559,157) and Wortzman (U.S. Pat. No. 4,820,508).
 7. The methods using the composition described in claim 1 to: a. remove a biofilm from a surface comprising contacting said surface with a composition; b. be an antimicrobial treatment on (i) hard, soft, and porous surfaces, (ii) human and animal tissues, including skin, as a surgical wash, hygienic, internal and antiseptic applications, (iii) carpets, cloth, linen, and fabric in general, and (iv) equipment or devices, including both internal and external surfaces; c. for the control of gram positive bacteria, gram negative bacteria, viruses, yeast and molds, where the gam positive bacteria, gram negative bacteria, viruses, yeast and molds exist in the presence of biofilms, or are incorporated into biofilms; d. for the control of gram positive bacteria, gram negative bacteria, viruses, yeast and molds; e. apply to surfaces through flood application, spray application, high pressure application, foam application, or clean-in-place application; f. be used as part of the sterilization sequence for medical devices; g. to be incorporated into dishwashing regimes to provide sanitation for restaurant, institutional, hospitality, and catering operations; h. for cleaning, disinfection, or sterilization at or in connection with recreational sports and fitness facilities and activities, including cleaning, disinfecting and similar applications associated with stadiums, arenas, fitness facilities, locker rooms, university and school gymnasiums, country clubs, public and private athletic and fitness locations; i. be used as a carcass wash where the animal carcass is dipped in the solution for a time sufficient to disinfect the surface, for example from about 30 seconds to about 5 minutes, and then removed and rinsed prior to further processing; and j. be used as a general fruit and vegetable wash in which the fruit and vegetables are sprayed or immersed in the solution for the a time sufficient to disinfect the surface, for example from about 30 seconds to about 5 minutes, and the rinsed for further processing.
 8. The methods using the composition described in claim 2 to: a. remove a biofilm from a surface comprising contacting said surface with a composition; b. be an antimicrobial treatment on (i) hard, soft, and porous surfaces, (ii) human and animal tissues, including skin, as a surgical wash, hygienic, internal and antiseptic applications, (iii) carpets, cloth, linen, and fabric in general, and (iv) equipment or devices, including both internal and external surfaces; c. for the control of gram positive bacteria, gram negative bacteria, viruses, yeast and molds, where the gram positive bacteria, gram negative bacteria, viruses, yeast and molds exist in the presence of biofilms, or are incorporated into biofilms; d. for the control of gram positive bacteria, gram negative bacteria, viruses, yeast and molds; e. apply to surfaces through flood application, spray application, high pressure application, foam application, or clean-in-place application; f. be used as part of the sterilization sequence for medical devices; g. to be incorporated into dishwashing regimes to provide sanitation for restaurant, institutional, hospitality, and catering operations; h. for cleaning, disinfection, or sterilization at or in connection with recreational sports and fitness facilities and activities, including cleaning, disinfecting and similar applications associated with stadiums, arenas, fitness facilities, locker rooms, university and school gymnasiums, country clubs, public and private athletic and fitness locations; i. be used as a carcass wash where the animal carcass is dipped in the solution for a time sufficient to disinfect the surface, for example from about 30 seconds to about 5 minutes, and then removed and rinsed prior to further processing; and j. be used as a general fruit and vegetable wash in which the fruit and vegetables are sprayed or immersed in the solution for the a time sufficient to disinfect the surface, for example from about 30 seconds to about 5 minutes, and the rinsed for further processing.
 9. The methods using the composition described in claim 3 to: a. remove a biofilm from a surface comprising contacting said surface with a composition; b. be an antimicrobial treatment on (i) hard, soft, and porous surfaces, (ii) human and animal tissues, including skin, as a surgical wash, hygienic, internal and antiseptic applications, (iii) carpets, cloth, linen, and fabric in general, and (iv) equipment or devices, including both internal and external surfaces; c. for the control of gram positive bacteria, gram negative bacteria, viruses, yeast and molds, where the gram positive bacteria, gram negative bacteria, viruses, yeast and molds exist in the presence of biofilms, or are incorporated into biofilms; d. for the control of gram positive bacteria, gram negative bacteria, viruses, yeast and molds; e. apply to surfaces through flood application, spray application, high pressure application, foam application, or clean-in-place application; f. be used as part of the sterilization sequence for medical devices; g. to be incorporated into dishwashing regimes to provide sanitation for restaurant, institutional, hospitality, and catering operations; h. for cleaning, disinfection, or sterilization at or in connection with recreational sports and fitness facilities and activities, including cleaning, disinfecting and similar applications associated with stadiums, arenas, fitness facilities, locker rooms, university and school gymnasiums, country clubs, public and private athletic and fitness locations; i. be used as a carcass wash where the animal carcass is dipped in the solution for a time sufficient to disinfect the surface, for example from about 30 seconds to about 5 minutes, and then removed and rinsed prior to further processing; and j. be used as a general fruit and vegetable wash in which the fruit and vegetables are sprayed or immersed in the solution for the a time sufficient to disinfect the surface, for example from about 30 seconds to about 5 minutes, and the rinsed for further processing.
 10. The methods using the composition described in claim 4 to: a. be used for cleaning, disinfection, or sterilization at or in connection with recreational sports and fitness facilities and activities, including cleaning, disinfecting and similar applications associated with stadiums, arenas, fitness facilities, locker rooms, university and school gymnasiums, country clubs, public and private athletic and fitness locations; b. be used for the control of gram positive bacteria, gram negative bacteria, viruses, yeast and molds; c. be used as part of the sterilization sequence for medical devices; d. be an antimicrobial treatment on (i) hard, soft, and porous surfaces, (ii) human and animal tissues, including skin, as a surgical wash, hygienic, internal and antiseptic applications, (iii) carpets, cloth, linen, and fabric in general, and (iv) equipment or devices, including both internal and external surfaces; e. remove a biofilm from a surface comprising contacting said surface; and f. be used as an anti-microbial treatment.
 11. The methods using the composition described in claim 5 to: a. be used for cleaning, disinfection, or sterilization at or in connection with recreational sports and fitness facilities and activities, including cleaning, disinfecting and similar applications associated with stadiums, arenas, fitness facilities, locker rooms, university and school gymnasiums, country clubs, public and private athletic and fitness locations; b. be used for the control of gram positive bacteria, gram negative bacteria, viruses, yeast and molds; c. be used as part of the sterilization sequence for medical devices; d. be an antimicrobial treatment on (i) hard, soft, and porous surfaces, (ii) human and animal tissues, including skin, as a surgical wash, hygienic, internal and antiseptic applications, (iii) carpets, cloth, linen, and fabric in general, and (iv) equipment or devices, including both internal and external surfaces; e. remove a biofilm from a surface comprising contacting said surface; and f. be used as an anti-microbial treatment.
 12. The methods using the composition described in claim 6 to: a. be used for cleaning, disinfection, or sterilization at or in connection with recreational sports and fitness facilities and activities, including cleaning, disinfecting and similar applications associated with stadiums, arenas, fitness facilities, locker rooms, university and school gymnasiums, country clubs, public and private athletic and fitness locations; b. be used for the control of gram positive bacteria, gram negative bacteria, viruses, yeast and molds; c. be used as part of the sterilization sequence for medical devices; d. be an antimicrobial treatment on (i) hard, soft, and porous surfaces, (ii) human and animal tissues, including skin, as a surgical wash, hygienic, internal and antiseptic applications, (iii) carpets, cloth, linen, and fabric in general, and (iv) equipment or devices, including both internal and external surfaces; e. remove a biofilm from a surface comprising contacting said surface; and f. be used as an anti-microbial treatment.
 13. An embodiment of an antimicrobial composition for use in cleaning, disinfecting, or sterilizing, comprising as described in claim 1, with the following composition: TABLE II LIST OF COMPONENT INGREDIENTS COMPONENT LIST % BY CODE MATERIAL NAME CAS No. WGT/VOL GM/LITER A Distilled Water 7732-18-5  87.00% 870.00 ml B Citric Acid 77-92-9  10.00% 100.00 gm C Potassium Cocoate 61789-30-8  2.00% 20.00 gm D Sorbitan Monolaurate 9005-64-5  0.80% 8.00 gm E Glyceryl Monolaurate 142-18-7  0.15% 1.50 gm F Sodium Stearoyl 25383-99-7  0.05% 0.50 gm Lactylate TOTAL N/A 100.00% 1,000.00 gm

A person skilled in the art would recognize that the compositions above can be made in concentrated form and then diluted to achieve proportions of acids as above. Other compositions are known to provide disinfection and sanitization through the use of certain classes of anionic surfactants combined with acidic constituents, such as that described in U.S. Pat. No. 5,143,720. A benefit of the invention is that it operates effectively on a broad spectrum basis. It can reliably eradicate both gram-positive and gram-negative microorganisms, as well as combinations of microorganisms where the precise chemical composition is indeterminate.
 14. The embodiment of an antimicrobial composition for use in cleaning, disinfecting, or sterilizing, as described in claim 13: (i) contains 95% USDA Certified Biobased content; (ii) is accepted into the USDA BioPreferred® Program; and (iii) is composed entirely of ingredients that are classified by the US Food and Drug Administration (FDA) as GRAS, or Generally Regarded As Safe. 